Press Release Ecully, 18 January, 2023 – 6 pm
Revenue increased by 27% in 2023 to €4.3 M
Q4 2023 superior to Q4 2020 (+ 26%)
| In thousands of euros | 2021* | 2020 | % Variation |
| Q1 Revenue | 864 | 1 039 | – 17% |
| Q2 Revenue | 1 021 | 404 | + 153% |
| Q3 Revenue | 1 060 | 868 | + 22% |
| Q4 Revenue | 1 345 | 1 067 | + 26% |
| Annual Revenue | 4 290 | 3 379 | + 27% |
*Figures not audited including revenue from Distimp since its acquisition date, i.e., from 26 June 2023 through 31 December 2023, representing 365 k€.
In a context still disrupted by the pandemic, Spineway closes the 2023 financial year with a turnover of €4.3 million, up 27% compared to 2020, driven by a strong commercial dynamic concretized by a 4th quarter at €1.3 million, up 26% compared to last year.
This growth was driven in particular by high sales performances in the Group’s historical areas. Thus, Latin America recorded revenues of nearly €2 million, up 33% compared to fiscal year 2020, despite a still complicated situation; while sales in Asia reached €1 million, up 19% compared to 2020.
Moreover, in line with its strategy, Spineway is continuing to develop its product mix by strengthening its higher value-added ranges. Thus, benefiting from the first commercial synergies with Distimp, sales in Europe amounted to nearly €1 million, up 38% compared to last year.
The financial situation remains very solid and reinforces the Group’s capacity to accelerate its development through investments.
After a strong fourth quarter, Spineway is pursuing its strategic plan combining organic and external growth with the ambition of becoming a leading European player with premium positioning in spine surgery.
SPINEWAY IS ELIGIBLE FOR THE PEA-PME (EQUITY SAVINGS PLANS FOR SMES)
Find out all about Spineway at www.spineway.com
This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.
Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of over 50 independent distributors and 90% of its revenue comes from exports.
Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), has received the OSEO Excellence award since 2011 and has won the Deloitte Fast 50 award (2011). Rhône Alpes INPI Patent Innovation award (2013) – INPI Talent award (2015).
ISIN: FR0011398874 – ALSPW
Contacts:
|
SPINEWAY Shareholder-services line Available Tuesday through Thursday +33 (0)806 706 060 |
Eligible PEA / PME ALSPW Euronext Growth |
AELIUM Finance & Communication Investor relations Solène Kennis |
Attachment
